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Abstract: 
The purpose of this study was to provide some benzimidazole derivatives as angiotensin converting enzyme (ACE) 
inhibitor. Based on the literature, a total of 19 benzimidazole derivatives were selected for molecular modelling 
study using the Autodock Vina software. The molecular modelling revealed that compound 10, 16, and 18 had 
binding affinity with the ACE enzyme closer to the binding affinity of lisinopril. To obtain the compounds 10, 16 and 
18, the 2-(butylsulfanyl)-1H-benzimidazole was treated with 2-fluorophenacylbromide, 2-methylphenacylbromide, 
and 3-nitrophenacylbromide, respectively. The structures of these compounds were confirmed on the basis of their 
spectral data (IR, 1H-NMR, and 13C-NMR). The synthesized compounds were subjected for their in vitro ACE 
inhibitory assay using Dojindo ACE Kit-WST test kit, Dojindo Laboratories, Kumamoto, Japan. It was observed that 
the compounds 10 and 16 had IC50 values less than the standard drug Lisinopril and have the required attributes to 
become potential candidates as an ACE inhibitor. However, further studies are recommended to ensure their 
efficacy and safety in different animal models. 
Key Words: Molecular modelling, Autodock Vina, Synthesis, Benzimidazole derivatives, ACE inhibitors. 
Corresponding author: 
Mohd. Imran, 
Department of Pharmaceutical Chemistry, 
Faculty of Pharmacy, Northern Border University, 
Rafha 91911, P.O. Box 840,  
Kingdom of Saudi Arabia. 
E-mail: imran_inderlok@yahoo.co.in 
Mobile Number: +966599577945 
Please cite this article in press as Mohd. Imran et al, molecular Modelling Studies and Synthesis of Some 
Benzimidazole Derivatives as Angiotensin Converting Enzyme Inhibitors, Indo Am. J. P. Sci, 2017; 4(04). 
QR code 
 
IAJPS 2017, 4 (04), 840-851                          Mohd. Imran et al                        ISSN 2349-7750 
 
 
  w w w . i a j p s . c o m  
 
Page 841 
INTRODUCTION: 
Hypertension has become a leading cause of human 
morbidity and mortality. According to World Health 
Organization [1], about 40% of people aged 25 and 
above are suffering from hypertension worldwide. 
According to recent studies [2, 3], the burden of 
hypertension is increasing at an alarming rate in Gulf 
region including in the Kingdom of Saudi Arabia. 
These studies have also stated that if the burden of 
hypertension remains uncontrolled, it will lead to 
major challenges to the health care system. 
Accordingly, efforts should be made to reduce the 
burden of hypertension worldwide.  
Angiotensin Converting Enzyme (ACE) [4] is an 
enzyme that converts Angiotensin I to Angiotensin II 
[4]. Angiotensin II is a potent vasoconstrictor and is 
implicated in the development of hypertension. 
Therefore, drugs that prevent the generation of 
Angiotensin II from Angiotensin I by inhibiting the 
Angiotensin Converting Enzyme (ACE) as well as 
the drugs that are Angiotensin II receptor antagonists 
are in clinical use as antihypertensive agents, for 
example, captopril [5], enalapril [6], lisinopril [7], 
telmisartan [8], candesartan [9], and azilsartan [10]. 
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However, many side effects are also associated with 
these drugs, for example, proteinurea, rashes, bad 
mouth odor, arrhythmia, allergic reactions, 
pancreatitis, alopecia, angioedema, and 
gastrointestinal disorders. Therefore, scientists are 
working to develop new ACE inhibitors as well as 
Angiotensine II receptor antagonists that are safer 
and effective than these existing drugs. 
Benzimidazole derivatives are reported to possess 
diverse biological activities [11,12]. Benzimidazole 
derivatives have also been reviewed as 
antihypertensive agents including as inhibitors of the 
Angiotensin Converting Enzyme (ACE) [13-15]. 
Therefore, it was aimed to perform molecular 
modelling studies and to synthesize some 
benzimidazole derivatives as angiotensin converting 
enzyme inhibitors. 
 
MATERIALS AND METHODS: 
Molecular Docking Methodology 
Docking studies were carried out by using AutoDock 
Vina software [16], running on Linux Ubuntu 12.0, 
installed on Pentium i3 workstation. The program 
AutoDock Tools (ADT) released as an extension 
suite to the Python Molecular Viewer was used to 
prepare the protein and the ligand to convert the 
molecules into Autodock type, which is a prerequisite 
for the docking [17, 18]. Discovery studio 4 [19] was 
used for visualizing the resolutions of docked 
conformations. ChemDraw ultra 8.0 software 
[Chemical Structure Drawing Standard; Cambridge 
Soft corporation, USA (2003)] was used for 
construction of compounds which were transformed 
to 3D structures using Chem 3D ultra 8.0 software 
and the constructed 3D structures were energetically 
minimized by using MOPAC (semiempirical 
quantum mechanics) with the AM1 mozyme 
geometry, 100 iterations and minimum RMS gradient 
of 0.10. For each ligand, corresponding 
ATOM/HETATM and CONECT records were 
extracted from protein complex in the pdb file. After 
assigning bond orders, missing hydrogen atoms were 
added. Then in the AutoDock tools package, the 
partial atomic charges were calculated using 
Gasteiger-Marsili method [20] and after merging non-
polar hydrogens, rotatable bonds were assigned. For 
receptor, the ligand, as well as any additional chains 
and all the heteroatoms including water molecules 
were removed. By the use of AutoDock Tools all 
missing hydrogens were added. Input molecule files 
for an AutoDock experiments must conform to the set 
of atom types supported by it. Therefore, pdbqt 
format was used to write ligands, recognized by 
AutoDock. The grid maps were calculated using 
AutoGrid [21]. In all dockings, a grid map with 60 x 
60 x 60 points, a grid spacing of 0.503 A° were used, 
and the maps were centered on the ligand binding 
site. All the compounds taken under study were 
modeled by positioning them in the LPR (PDB ID: 
1O86) binding site in the active domain of ACE 
protein as accorded by the published crystal structure. 
From the comparative docking study of our 
compounds with standard binding compound (LPR) 
we could observe how our compounds might bind to 
the ACE inhibition site, based on the knowledge of 
the structure of similar active sites. We redocked LPR 
into the active site of the protein and then we docked 
with our compounds in order to compare the binding 
affinity of both ligand and the test compounds. The 
docking score of the targeted compounds is also 
provided in Table 1. 
 
Table 1: Docking scores of the selected compounds and the physical constants of the synthesized compounds 
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Compound 
Number 
R Molecular 
Formula 
M.P. 
(±2oC) 
Yield 
(%) 
Rf Value Docking 
Score 
1 H C19H20N2OS - - - -7.9 
2 4-Br C19H19BrN2OS - - - -7.4 
3 3-Br C19H19BrN2OS - - - -7.8 
4 2-Br C19H19BrN2OS - - - -7.6 
5 2-Cl C19H19ClN2OS - - - -7.3 
6 3-Cl C19H19ClN2OS - - - -7.6 
7 4-Cl C19H19ClN2OS - - - -7.8 
8 4-F C19H19FN2OS - - - -7.8 
9 3-F C19H19FN2OS - - - -7.8 
10 2-F C19H19FN2OS 166 55 0.81 -8 
11 2-OCH3 C20H22N2O2S - - - -7.7 
12 3-OCH3 C20H22N2O2S - - - -7.7 
13 4-OCH3 C20H22N2O2S - - - -7.5 
14 4-CH3 C20H22N2OS - - - -7.4 
15 3-CH3 C20H22N2OS - - - -7.7 
16 2-CH3 C20H22N2OS 143 70 0.77 -8.1 
17 2-NO2 C19H19N3O3S - - - -7.7 
18 3-NO2 C19H19N3O3S 155 60 0.79 -8.2 
19 4-NO2 C19H19N3O3S - - - -7.7 
Lisinopril - - - - - -8.3 
 
Chemistry 
Melting points were recorded in open capillary tubes 
and are uncorrected. IR (KBr) spectra were recorded 
on a JASCO, FTIR-4100 spectrophotometer. The 1H-
NMR and 13C-NMR spectra were recorded on Bruker 
Ultrashield 500 Plus MHz spectrophotometer. All 
reagents used in the present work were of analytical 
grade. The standard drug Lisinopril used for the 
assessment of in vitro ACE inhibitory activity was 
procured from Sigma Aldrich, USA. The purity of 
the compounds was checked on silica gel G plates 
using iodine vapours as visualizing agent. The Rf 
value of the compounds was determined by using a 
mixture of benzene and acetone (9:1). The synthetic 
pathway for the preparation of the benzimidazole 
derivatives is provided in Scheme 1. 
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Synthesis of 2-(butylsulfanyl)-1H-benzimidazole 
1H-Benzimidazole-2-thiol (0.01 mol) and sodium 
hydroxide (0.01 mol) were mixed in 20 ml of ethanol 
and the mixture was heated for 1 hour. Butyl bromide 
(0.02 mol) was added to the mixture and the resulting 
mixture was refluxed for 8 hours. The contents were 
reduced to half of its volume and then poured on 
crushed ice. The solid was filtered, washed with 
water and recrystallized from ethanol. m.p. 133-
135oC; Yield: 50%; Rf value: 0.88; IR (KBr) cm-1: 
3440 (N-H), 2950, 1330, 1394; 1H-NMR (DMSO-d6, 
δ ppm): 0.85 (t, 3H), 1.28-1.48 (m, 2H), 1.62-1.73 
(m, 2H), 3.25 (t, 2H), 7.03-7.17 (m, 2H), 7.35-7.55 
(m, 2H), 12.33 (1H, bs). 
 
General procedure for the synthesis of the 
targeted compounds 
2-(Butylsulfanyl)-1H-benzimidazole (0.01 mol) was 
dissolved in 25 ml of acetone. Potassium carbonate 
(0.015 mol) was added to the mixture and the mixture 
was stirred for about 30 minutes. Appropriate 
phenacyl bromide (0.01 mole) was added to the 
resulting mixture and it was stirred for 20 hours. The 
contents of the flask were reduced to half of its 
volume and it was poured on crushed ice. The solid 
separated was filtered, washed with water and 
recrystallized from ethanol. 
 
Angiotensin Converting Enzyme Inhibitory Assay 
The compounds (10, 16 and 18) that showed highest 
ACE inhibitory activity, according to the molecular 
modelling studies were subjected for the ACE 
inhibitory assay using Dojindo ACE Kit-WST test 
kit, Dojindo Laboratories, Kumamoto, Japan [22]. 
The enzymatic reaction was initiated by the ACE and 
aminoacylase in the mixture containing 3HB-GGG 
(3-hydroxybutyrate glycylglycylglycine) and the 
ACE-inhibitor. The mixture was then incubated at 
37oC for 60 minutes. During this incubation, the 
substrate, 3HB-GGG, was enzymatically cut into 
3HB-G and G-G and then 3HB and G. The yield of 
3HB was monitored indirectly through formazan 
concentration, which was measured at 450 nm after 
10 minute reaction at 25oC. Testing procedures were 
run according to the manufacturer’s instructions 
using a 96-well plate without modification, and the 
inhibition rate was calculated based on a comparison 
of the optical absorbance of samples-treated wells 
(𝐴𝑠), control wells (𝐴𝑐), and blank wells (𝐴𝑏). 
Absorbance was measured at 450 nm using the 
microplate reader Biotek-ELX800 (BioTek, 
Vermont, USA). Inhibition rates were calculated 
using the following equation. 
 
Inhibition rate (%) = [𝐴𝑐 – 𝐴𝑠 / 𝐴𝑐 − 𝐴𝑏] × 100 
 
Samples were suspected to inhibit the ACE activity, 
and therefore inhibit the formation of formazan. The 
more strongly inhibitory the activity of the samples, 
the less color appeared in the final solution. 
 
Statistical Analysis 
All ACE inhibitory activity data are presented as 
mean ± standard deviation (SD, n = 3). The data were 
analyzed by one-way analysis of variance (ANOVA) 
with Dunnett’s Multiple Comparison Test with 
respect to control group and standard groups using 
GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego California USA). 
The results were considered significantly different at 
p < 0.05. The IC50 values were determined by linear 
regression calculator of GraphPad software. 
 
RESULTS: 
Molecular Docking Study 
The docking data of Lisinopril with the ACE protein 
revealed that the original co-crystallized and docked 
ligand overlapped with ACE protein elegantly, 
thereby validating our docking study. The results of 
docking scores in terms of binding affinity have been 
summarized in Table 1. The lisinopril exhibited 
binding affinity of -8.3 kcal/mol with the ACE 
protein and interacted with the Glu-162, Asn-277, 
Asn-281, His-383 and Tyr-523 by forming 
conventional H-bond as shown in 2D-diagram of 
ligand protein interaction (Figure 1). Interestingly, 
compounds 10 (Figure 2), 16 (Figure 3), and 18 
(Figure 4) also showed binding affinity close to 
Lisinopril. The compound 10 exhibited binding 
affinity of -8.0 kcal/mol; the compound 16 exhibited 
binding affinity of -8.1 kcal/mol; and the compound 
18 exhibited binding affinity of -8.2 kcal/mol. 
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Fig 1: 2D interaction of lisinopril with the active sites of the ACE 
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Fig 2: 2D interaction of compound 10 with the active sites of the ACE 
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Fig 3: 2D interaction of compound 16 with the active sites of the ACE 
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Fig 4: 2D interaction of compound 18 with the active sites of the ACE 
IAJPS 2017, 4 (04), 840-851                          Mohd. Imran et al                        ISSN 2349-7750 
 
 
  w w w . i a j p s . c o m  
 
Page 849 
Chemistry 
The benzimidazole derivatives were prepared 
according to the method provided in Scheme 1. The 
compound o-phenylenediamine was reacted with 
carbon disulfide in the presence of potassium 
hydroxide to obtain 1H-benzimidazole-2-thiol. The 
1H-benzimidazole-2-thiol was treated with butyl 
bromide in the presence of sodium hydroxide to 
provide 2-(Butylsulfanyl)-1H-benzimidazole. The 2-
(butylsulfanyl)-1H-benzimidazole was treated with 2-
fluorophenacylbromide, 2-methylphenacylbromide, 
and 3-nitrophenacylbromide to obtain the targeted 
compounds 10, 16 and 18, respectively. The structure 
of these compounds was confirmed on the basis of 
following data. 
 
2-[2-(butylsulfanyl)-1H-benzimidazol-1-yl]-1-(2-
fluorophenyl)ethanone (Compound 10): IR (KBr) 
cm-1: 2955, 1700 (C=O), 1335, 1390; 1H-NMR 
(DMSO-d6, δ ppm): 0.90 (t, 3H), 1.29-1.42 (m, 2H), 
1.61-1.71 (m, 2H), 3.21 (t, 2H), 5.80 (s, 2H), 7.10-
7.41 (m, 4H), 7.55-7.81 (m, 4H); 13C-NMR (DMSO-
d6, δ ppm): 12.3, 20.5, 31.3, 35.3, 55.0, 109.1, 114.1, 
114.3, 122.1 (2), 124.5, 126.1, 126.6, 133.5, 133.8, 
137.8, 151.5, 161.1, 170.8. 
 
2-[2-(butylsulfanyl)-1H-benzimidazol-1-yl]-1-(2-
methylphenyl)ethanone (Compound 16): IR (KBr) 
cm-1: 2950, 1695 (C=O), 1330, 1395; 1H-NMR 
(DMSO-d6, δ ppm): 0.88 (t, 3H), 1.30-1.41 (m, 2H), 
1.62-1.72 (m, 2H), 3.23 (t, 2H), 5.78 (s, 2H), 7.13-
7.41 (m, 4H), 7.54-7.84 (m, 4H); 13C-NMR (DMSO-
d6, δ ppm): 12.3, 17.5, 20.5, 31.3, 35.3, 55.3, 109.1, 
114.1, 122.1 (2C), 124.5, 126.4, 130.2, 132.1, 133.1, 
133.7, 136.2, 137.8, 151.5, 170.9. 
 
2-[2-(butylsulfanyl)-1H-benzimidazol-1-yl]-1-(3-
nitrophenyl)ethanone (Compound 18): IR (KBr) 
cm-1: 2955, 1695 (C=O), 1330, 1395; 0.89 (t, 3H), 
1.30-1.41 (m, 2H), 1.62-1.70 (m, 2H), 3.23 (t, 2H), 
5.79 (s, 2H), 7.13-7.40- (m, 4H), 7.52-7.80 (m, 4H); 
13C-NMR (DMSO-d6, δ ppm): 12.3, 20.5, 31.3, 35.3, 
55.0, 109.1, 114.1, 121.3, 122.1 (2C), 127.2, 128.4, 
133.1, 133.8, 136.5, 137.8, 146.7, 151.5, 170.8. 
 
ACE inhibitory activity 
 
Based on the molecular modelling results, the 
compounds 10, 16 and 18 were selected for further in 
vitro ACE inhibitory assay using Dojindo ACE Kit-
WST test kit, Dojindo Laboratories, Kumamoto, 
Japan. The ACE inhibitory activity data of these 
compounds are provided in Table 2. 
 
Table 2: In vitro ACE inhibitory activity of the synthesized benzimidazole derivatives 
 
Compound Concentration 
(μg/mL) 
%ACE 
Inhibition 
(Mean ± SD) 
IC50 
(μg/mL) 
Docking 
Score 
 
 
Lisinopril 
1 41.10 ± 0.22*  
0.4 
 
-8.3 
 
2 62.11 ± 0.12* 
4 77.61 ± 0.09* 
8 88.16 ± 0.55* 
 
Compound 10 
1 38.11 ± 0.22*  
0.37 
 
-8 2 60.01 ± 0.41* 
4 75.11 ± 0.46* 
8 84.60 ± 0.11 
 
 
Compound 16 
1 38.33 ± 0.55*  
0.36 
 
-8.1 2 61.89 ± 0.42* 
4 77.11 ± 0.31* 
8 86.16 ± 0.17* 
 
 
Compound 18 
1 40.22 ± 0.18*  
1.92 
 
-8.2 2 63.81 ± 0.14* 
4 78.0 ± 0.16* 
8 88.66 ± 0.35* 
*p < 0.05; n = 3. 
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DISCUSSION: 
Based on the literature [11-15], 19 benzimidazole 
derivatives were selected for molecular modelling 
study with the expectation that these compounds may 
provide good ACE inhibitory activity. The structure 
of these compounds is provided in Table 1. The 
molecular modelling study revealed that the 
compound 10, 16, and 18 had binding affinity with 
ACE enzyme closer to the binding affinity of 
lisinopril. These compounds were synthesized by the 
treatment of 2-(butylsulfanyl)-1H-benzimidazole 
with 2-fluorophenacylbromide, 2-
methylphenacylbromide, and 3-nitrophenacylbromide 
to obtain the compounds 10, 16 and 18, respectively. 
The structures of these compounds were confirmed 
on the basis of their spectral data (IR, 1H-NMR, and 
13C-NMR). The synthesized compounds were 
subjected for their in vitro ACE inhibitory assay 
using Dojindo ACE Kit-WST test kit, Dojindo 
Laboratories, Kumamoto, Japan. The ACE inhibitory 
activity of these compounds revealed that the 
compound 10 had an IC50 value of 0.37 μg/mL; the 
compound 16 had an IC50 value of 0.36 μg/mL; the 
compound 18 had an IC50 value of 1.92 μg/mL; and 
lisinopril had an IC50 value of 0.40 μg/mL. These 
results suggest that the compound 10 and the 
compound 16 are better ACE inhibitors than 
Lisinopril. Contrary to the results of molecular 
docking score of the compound 18, it did not show 
expected results in in vitro ACE inhibitory assay. 
 
CONCLUSION: 
Based on the results it has been concluded that the 
compounds 10 and 16 had IC50 values less than the 
standard drug lisinopril and they also have the 
required pharmacodynamics attributes to become 
potential candidates as an ACE inhibitors. However, 
further studies are recommended to ensure their 
efficacy and safety in different animal models. 
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